Astrocyte metabolism of the medium-chain fatty acids octanoic acid and decanoic acid promotes GABA synthesis in neurons via elevated glutamine supply

Jens V. Andersen1*, Emil W. Westi1, Emil Jakobsen1, Nerea Urruticoechea1, Karin Borges2 and Blanca I. Aldana1*

Abstract
The medium-chain fatty acids octanoic acid (C8) and decanoic acid (C10) are gaining attention as beneficial brain fuels in several neurological disorders. The protective effects of C8 and C10 have been proposed to be driven by hepatic production of ketone bodies. However, plasma ketone levels correlates poorly with the cerebral effects of C8 and C10, suggesting that additional mechanism are in place. Here we investigated cellular C8 and C10 metabolism in the brain and explored how the protective effects of C8 and C10 may be linked to cellular metabolism. Using dynamic isotope labeling, with [U-13C]C8 and [U-13C]C10 as metabolic substrates, we show that both C8 and C10 are oxidatively metabolized in mouse brain slices. The 13C enrichment from metabolism of [U-13C]C8 and [U-13C]C10 was particularly prominent in glutamine, suggesting that C8 and C10 metabolism primarily occurs in astrocytes. This finding was corroborated in cultured astrocytes in which C8 increased the respiration linked to ATP production, whereas C10 elevated the mitochondrial proton leak. When C8 and C10 were provided together as metabolic substrates in brain slices, metabolism of C10 was predominant over that of C8. Furthermore, metabolism of both [U-13C]C8 and [U-13C]C10 was unaffected by etomoxir indicating that it is independent of carnitine palmitoyltransferase I (CPT-1). Finally, we show that inhibition of glutamine synthesis selectively reduced 13C accumulation in GABA from [U-13C]C8 and [U-13C]C10 metabolism in brain slices, demonstrating that the glutamine generated from astrocyte C8 and C10 metabolism is utilized for neuronal GABA synthesis. Collectively, the results show that cerebral C8 and C10 metabolism is linked to the metabolic coupling of neurons and astrocytes, which may serve as a protective metabolic mechanism of C8 and C10 supplementation in neurological disorders.

Keywords: MCT, MCFA, Neurotransmitter recycling, Mitochondria, β-hydroxybutyrate, Caprylic acid (C8), Capric acid (C10)

Introduction
Glucose is the primary fuel of the brain. However, brain cells can utilize several other metabolic substrates including amino acids, ketone bodies and fatty acids [1]. Medium-chain fatty acids (MCFAs) are gaining attention as brain fuels [2–4]. Diets enriched with medium-chain triglycerides (MCTs) of octanoic acid (C8) and decanoic acid (C10) have shown beneficial effects in
neurodegenerative diseases [5]. In patients with mild cognitive impairment and Alzheimer’s disease, supplementation of C8 and C10 has been shown to improve both cognition and brain energy metabolism [6–8]. Furthermore, MCT supplementation appears to be efficient in the management of drug-resistant epilepsy [9–11]. Ketone body production driven by hepatic metabolism of C8 and C10 has been suggested to be the main mechanism underlying the anti-epileptic effects of the MCT diet [9]. However, studies have found poor correlation between seizure control and plasma ketone levels [12, 13]. Both C8 and C10 are able to cross the blood brain barrier [14, 15] and can reach cerebral concentrations of 200 µM in mice after enriched feeding [16, 17]. As C8 and C10 are well-known metabolic substrates in the periphery [2], they may serve specific metabolic purposes in the brain as well.

Neurons and astrocytes function in close metabolic collaboration [18]. The energy metabolism of neurons and astrocytes is closely linked to both synthesis and metabolism of glutamate and GABA, being the primary excitatory and inhibitory neurotransmitters of the brain, respectively [19, 20]. Astrocytes take up a large fraction of the released glutamate and GABA from the synapse, and in turn, provide neurons with glutamine, which is an essential substrate for re-synthesis of glutamate and GABA in the neurons [21, 22]. Inadequate astrocyte glutamine synthesis has been reported in multiple diseases, including epilepsy, and experimental inhibition of glutamine synthesis leads to seizures [23–25]. Glutamine is exclusively synthesized in astrocytes from glutamate catalyzed by the enzyme glutamine synthetase (GS) [26]. This process is closely linked to cellular energy metabolism as the tricarboxylic acid (TCA) cycle intermediate α-ketoglutarate serves as the precursor of glutamate synthesis and hereby also glutamine synthesis in astrocytes [27]. In the mitochondria, C8 and C10 are converted by β-oxidation into acetylCoA units, which can enter the TCA cycle and hereby support cellular metabolism. Previous studies have suggested that astrocytes may be the main metabolic compartment for C8 metabolism in the brain [28–30]. However, brain metabolism of C8 and C10 and how this may be linked to neurotransmitter recycling, has not been explored in detail.

The aim of this study was therefore to provide a better understanding of cellular C8 and C10 metabolism in the brain. To achieve this we mapped C8 and C10 metabolism in acutely isolated cerebral cortical slices by using 13C isotopically enriched C8 and C10 with subsequent gas chromatography-mass spectrometry (GC–MS) analysis. We also conducted metabolic competition assays between C8 and C10 and investigated the effects of carnitine palmitoyltransferase I (CPT-1) and GS inhibition.

Furthermore, we examined the effect of C8 and C10 supplementation on mitochondrial bioenergetics in cultured astrocytes. We provide evidence that both C8 and C10 are oxidatively metabolized in brain slices particularly promoting astrocyte glutamine synthesis. Notably, we demonstrate that the glutamine generated by C8 and C10 metabolism in astrocytes is utilized in neurons for GABA synthesis. Our results provide new insight into C8 and C10 metabolism in the brain and potential metabolic mechanisms of MCFA supplementation in different pathologies.

Methods

Materials

The stable 13C enriched compounds [U-13C]octanoic acid ([U-13C]C8, CLM-3981-PK, 98%), [U-13C]decanoic acid ([U-13C]C10, CLM-9950-PK, 98%) and [U-13C]β-hydroxybutyrate ([U-13C]βHB, CLM-3853-PK, sodium salt, 97%) were all from Cambridge Isotope Laboratories (Tewksbury, USA). Octanoic acid ([12C8, C2875), decanoic acid ([12C10, C1875), β-β-hydroxybutyrate (12C-βHB, 54920) oligomycin A (75351), carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP, C2920), antimycin A (A8674) rotenone (R8875), (+)-etomoxir (E1905, sodium salt) and 1-methionine sulfoximine (MSO, M5379) were from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals used were of the purest grade available from regular commercial sources.

Animals

Male NMRI mice (Envigo, Cambridgeshire, United Kingdom) of 12 weeks of age (weight: 40.5 ± 0.5 g) were housed in a pathogen-free, temperature and humidity controlled environment at the Department of Drug Design and Pharmacology, University of Copenhagen. The mice were acclimatized for two weeks before experiments and were single-housed in individually ventilated cages with free access to chow and water.

Brain slice incubations

Incubation of acutely isolated cerebral cortical mouse brain slices were performed as previously described [31], with slight modifications. Briefly, a mouse was euthanized by cervical dislocation and decapitated. The brain was transferred to ice-cold artificial cerebrospinal fluid (ACSF) containing in mM: NaCl 128, NaHCO3 25, d-glucose 10, KCl 3, CaCl2 2, MgSO4 1.2, KH2PO4 0.4, pH = 7.4. The cerebral cortex was dissected and sliced (350 µm) using a McIlwain tissue chopper (The Vibratome Company, O’Fallon, MO, USA). The cerebral cortical slices were kept just below the surface of 10 mL 37 °C oxygenated (5% CO2/95% O2) ACSF and pre-incubated for 60 min. Subsequently, the media were
exchanged for ACSF containing the stable 13C enriched compounds (12 mL in glass tubes to avoid fatty acid adherence to plastic) supplemented with 5 mM unlabelled d-glucose and incubated for additional 60 min. Two round of slices incubation experiments were performed. In the first round, a competition assay was performed in which the slices were incubated in the presence of either [U-13C]C8, [U-13C]C10 or [U-13C]βHB (all 200 µM) ± competing unlabeled 12C substrates: 12C8, 12C10 or 12C-βHB (also 200 µM). Media contain-
mol metabolites of interest. Metabolism of 13C enriched substrates can give rise to complex labeling patterns with multiple 13C isotopologues which are metabolites differing in their 13C composition (denoted as M + X, where M is the molecular ion of the metabolite and X is the number of 13C atoms) as described in [34]. Here data is presented as the molecular carbon labeling (MCL), which is the weighted average of all the different isotopologues of a metabolite [35]. The MCL thus provides a measurement of the overall 13C accumulation in a given metabolite and is calculated as:

\[
\text{MCL} = \frac{(M + 1 \times 1) + (M + 2 \times 2) + (M + 3 \times 3) + \ldots + (M + X \times X)}{\text{Total number of carbon atoms in molecule}}
\]

Determination of amino acid amounts by high-performance liquid chromatography (HPLC) analysis
Aqueous extracts of the brain slices were analyzed by reverse-phase HPLC (Agilent Technologies, 1260 Infinity, Agilent ZORBAX Eclipse Plus C18 column) to quantitatively determine the amounts of the following amino acids: aspartate, glutamate, glutamine, taurine & GABA [36]. A pre-column derivatization with o-phthalaldehyde and fluorescent detection, λex = 338 nm, λem = 390 nm, was performed. Gradient elution with mobile phase A (10 mM NaH2PO4, 10 mM Na2B4O7, 0.5 mM NaN3, pH 8.2) and mobile phase B (acetonitrile 45%; methanol 45%; H2O 10%, V:V:V) was performed. The amounts of amino acids were determined from analysis of standards of the amino acids of interest. The amino acid amounts of the slice extracts were adjusted to the protein amounts of the slices and are presented as nmol/mg protein.

Primary cultures of cortical astrocytes and determination of oxygen consumption rate (OCR)
Primary cultures of cortical astrocytes were prepared from 7-day-old NMRI mouse pups as previously described [34]. Each plate of cortical astrocytes were prepared from individual batches of pups. Briefly, pups were decapitated and the cerebral cortex excised. The tissue was processed by passage through a 80 µm pore size nylon mesh and submersed in a modified Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 2.5 mM l-glutamine, 6 mM glucose, 100,000 i.u. penicillin, 0.04 mM phenol red, 26.2 mM NaHCO3 and 20% (v/v) fetal bovine serum. A steel cannula fitted to a syringe was used to dissociate the cells by trituration. The cell suspension was plated in Seahorse XFe96-well culture plates and cultured for 21 days at 37 °C in a humidified atmosphere of 5% CO2/95% air. Medium was exchanged twice a week and serum concentration
reduced to 15% in the second week and 10% in the third week and 0.25 mM dibutyryl-cAMP (final concentration) was added to the medium for the last week of culture. The oxygen consumption rate (OCR) of the cultured astrocytes were determined using a Seahorse XFe96 analyzer as previously described [37]. Briefly, the astrocytes were washed twice and the media changed to Seahorse assay medium (DMEM with 2.5 mM glucose and 3 mg/L phenol red, pH 7.4) and kept at 37 °C (non-CO2 incubator) for 1 h. When indicated the assay medium was further supplemented with C8, C10 or the combination (all 200 µM). As for the brain slice incubations, media containing C10 was prepared directly in Seahorse assay medium at a final concentration of 200 µM, whereas C8 was prepared as a 20 mM stock. In total, 12 measurement cycles (2 min mix, 1 min wait, 3 min measure) were performed (as outlined in Fig. 2B). After 3 initial baseline measurements, 3 injections were performed (all final concentrations): (1) 1.0 µM oligomycin A, (2) 0.5 µM FCCP, (3) 0.5 µM antimycin A and 0.5 µM rotenone. After each injection 3 measurement cycles were performed. The non-mitochondrial OCR was subtracted from all data points (Fig. 2B). To account for potential inter-well variability during the culturing period, data is presented as OCR as % of control (glucose condition).

Experimental design and statistical analyses
Data is presented as means ± standard error of the mean (SEM), with individual data points presented. Each data point (represented by circles in the graphs) represents biological replicates (i.e. from individual animals), which is denoted by 'n' in the figure legends. Statistical analyses were performed by repeated measurements 1-way ANOVA with Bonferroni correction for multiple comparisons. The significance level was set at p < 0.05 and is indicated with a single asterisk.

Results
Oxidative C8 and C10 metabolism promotes astrocyte glutamine synthesis in brain slices
To get an overview of the extent and possible compartmentation of C8 and C10 brain metabolism, we first incubated acutely isolated cerebral cortical slices in the presence of either [U-13C]C8 or [U-13C]C10 (Fig. 1). [U-13C]C8 and [U-13C]C10 will enter cellular metabolism as 13C enriched acetylCoA units and hereby give rise to 13C enrichment in TCA cycle intermediates and derived amino acids (presented as the average 13C accumulation, molecular carbon labeling, MCL [35]). In the TCA cycle, the highest 13C accumulation from both [U-13C]C8 and [U-13C]C10 metabolism was found in citrate (C8: 17.4 ± 0.2%, C10: 18.9 ± 0.8%), whereas it was much lower for α-ketoglutarate (C8: 5.4 ± 0.6%, C10: 5.9 ± 0.3%) and malate (C8: 6.5 ± 0.2%, C10: 6.5 ± 0.2%). Of the derived amino acids, the highest 13C accumulation was found in glutamine (C8: 28.5 ± 0.4%, C10: 35.0 ± 0.8%), whereas it was around four times lower for aspartate (C8: 5.8 ± 0.2%, C10: 5.4 ± 0.2%), glutamate (C8: 7.3 ± 0.2%, C10: 7.3 ± 0.3%) and GABA (C8: 7.9 ± 0.7%, C10: 6.4 ± 0.2%). The only difference between the two fatty acids was observed in glutamine, where metabolism of [U-13C]C10 led to larger 13C accumulation than [U-13C]C8. We found no differences in the absolute pool sizes of amino acids between the [U-13C]C8 and [U-13C]C10 incubations (Additional file 1: Table S1). These results show that both C8 and C10 are actively metabolized in brain slices and that the extent of metabolism between the two fatty acids is generally comparable. Furthermore, since glutamine is selectively synthesized in astrocytes [26], the preferential 13C accumulation in this amino acid suggesting that astrocytes are the primary cellular compartment of C8 and C10 metabolism in brain slices.

C8 and C10 stimulate mitochondrial respiration in cultured astrocytes
MCFAs can serve as metabolic substrates and support mitochondrial respiration in multiple tissues [2, 4]. To assess whether this was the case in astrocytes, we pre-incubated cultured astrocytes in media supplemented with C8, C10 or the combination in addition to glucose (Fig. 2A) and determined the oxygen consumption rate (OCR) using the Seahorse XFe96 flux analyzer (Fig. 2B). We found that C8, C10 and the combination increased the basal OCR of the cultured astrocytes (Fig. 2C). The basal OCR is comprised of the OCR related to ATP production and the proton leak (Fig. 2B), the latter reflecting the flow of protons across the mitochondrial membrane not linked to ATP production [38]. We found that the presence of C10 selectively elevated the proton leak in the cultured astrocytes (Fig. 2D), whereas C8 alone increased the OCR related to ATP production (Fig. 2E). Finally, when the oxidative capacity was unleashed by the uncoupling agent FCCP, we observed that C8, C10 as well as the combination, elevated the OCR of the cultured astrocytes (Fig. 2F). These results demonstrate that both C8 and C10 are able to stimulate respiration in cultured astrocytes, albeit via distinct mitochondrial mechanisms.

C10 is preferred over C8 as a metabolic substrate in brain slices
So far, we have shown that C8 and C10 can serve as metabolic substrates in astrocytes promoting glutamine synthesis and stimulating mitochondrial respiration. Next, we wanted to investigate if there was any metabolic
preference between the two fatty acids. To this end, we performed a competition assay, in which brain slices were incubated in the presence of either [U-13C]C8 or [U-13C]C10, but now also with a competing unlabeled (i.e. 12C) fatty acid (Fig. 3). Metabolism of an unlabeled 12C fatty acid will dilute the 13C labeling, and so the metabolic preference of each fatty acid can be determined. When the slices were exposed to [U-13C]C8 in the presence of unlabeled 12C10, we found large reductions in the 13C accumulation of all measured metabolites (in the range of 12–21% of control). In contrast, the metabolism of [U-13C]C10 was only found to be reduced in GABA (65.4 ± 3.4% of control) and glutamine (83.1 ± 1.7% of control) when unlabeled 12C8 was present. These results demonstrate that metabolism of C10 is predominant over that of C8 in the brain slices when the two fatty acids are provided together. Furthermore, we also included the ketone body β-hydroxybutyrate (βHB) in the competition experiments. βHB also enters metabolism as acetyl-CoA units, but is oxidized to a larger extent in neurons than in astrocytes [29, 39]. We found that unlabeled 12C-βHB had little influence on both [U-13C]C8 and [U-13C]C10 metabolism in the brain slices (Additional file 1: Fig. S1). Furthermore, metabolism of unlabeled 12C8 and 12C10 was only able to reduce the 13C accumulation from [U-13C]βHB metabolism in citrate and glutamine (Additional file 1: Fig. S2), confirming that the substrates are oxidized in separate cellular compartments. Again, no changes in the absolute pool sizes of amino acids were observed (Additional file 1: Table S1).
Metabolism of C8 and C10 is independent of carnitine palmitoyltransferase I in brain slices

Given that the extent of $^{13}$C accumulation between C8 and C10 was comparable when metabolized individually (Fig. 1), it was surprising that C10 was preferred over C8 so extensively when applied together (Fig. 3). This could be explained by C8 and C10 competing for the same transport mechanism. Cellular and mitochondrial uptake of MCFAs is driven by passive diffusion [2, 40]. However, in a neuronal-like cell line mitochondrial uptake of C8 and C10 was recently suggested to be partially mediated by carnitine palmitoyltransferase I (CPT-1), an enzyme important for long-chain fatty acid transport [41]. To investigate if this was the case in brain slices, we next examined the effect of the irreversible CPT-1 inhibitor etomoxir on metabolism of [U-$^{13}$C]C8 and [U-$^{13}$C]C10 (Fig. 4). Etomoxir was applied at 100 µM, which effectively inhibit long-chain fatty acid metabolism in both dissected brain tissue and cultured astrocytes [42]. We did not observe any significant alterations in $^{13}$C accumulation of the measured metabolites when etomoxir was present during the incubation. These results indicate that metabolism of both [U-$^{13}$C]C8 and [U-$^{13}$C]C10 is independent of CPT-1 in brain slices, and C8 and C10 must therefore enter the mitochondria via other mechanisms. As expected, metabolism of [U-$^{13}$C]βHB was likewise unaffected by etomoxir (Additional file 1: Fig. S3).

Astrocyte glutamine from C8 and C10 metabolism is utilized for neuronal GABA synthesis

To further explore the significance of the astrocyte glutamine synthesis from metabolism of C8 and C10, we finally investigated the effect of glutamine synthetase (GS) inhibition on metabolism of [U-$^{13}$C]C8 and [U-$^{13}$C]C10 in the cerebral cortical slices (Fig. 5). The GS inhibitor methionine sulfoximine (MSO) was applied at 5 mM, which we have previously shown is sufficient to effectively inhibit GS activity in brain slices [43]. As expected, GS inhibition abolished the $^{13}$C accumulation in glutamine from metabolism of [U-$^{13}$C]C8 and [U-$^{13}$C]C10 (C8: 8.7 ± 1.9% of control, C10: 3.7 ± 0.5% of control). Interestingly, all TCA cycle intermediates and the derived amino
acids aspartate and glutamate exhibited large increases in $^{13}$C accumulation from metabolism of [U-$^{13}$C]C8 and [U-$^{13}$C]C10 when glutamine synthesis was inhibited by MSO (in the range of 156–267% of control). In contrast, GS inhibition selectively led to large reductions in the $^{13}$C accumulation in GABA (C8: 23.4 ± 1.5% of control, C10: 25.4 ± 1.2% of control) from both [U-$^{13}$C]C8 and [U-$^{13}$C]C10 metabolism. Since astrocyte-derived glutamine is a crucial substrate for neuronal GABA synthesis [44], these results demonstrate that the glutamine synthesized by metabolism of C8 and C10 in astrocytes is utilized in neurons to maintain the GABA pool. MSO only decreased the $^{13}$C accumulation in glutamine, but not in GABA, from [U-$^{13}$C]βHB metabolism which is expected as βHB is primarily metabolized in neurons (Additional file 1: Fig. S4).

**Discussion**

Here we demonstrate that the MCFAs C8 and C10 are oxidatively metabolized in brain slices and promotes astrocyte glutamine synthesis. We found that the overall extent of metabolism was comparable between C8 and C10, but C10 was preferred over C8 as a metabolic substrate when both fatty acids were present. Both C8 and C10 stimulated mitochondrial respiration in cultured astrocytes, where C8 elevated respiration linked to ATP synthesis and C10 increased the mitochondrial proton leak. Finally, we found that metabolism of both C8 and C10 was CPT-1 independent and that the elevated astrocyte glutamine synthesis from C8 and C10 metabolism is utilized for neuronal GABA synthesis in the brain slices (findings summarized in Fig. 6).
**Astrocyte metabolism of C8 and C10**

MCFAs have long been known to be substrates, albeit minor ones, for cerebral oxidative metabolism [1, 4, 45]. It has previously been reported that in-vivo metabolism of radiolabeled C8 leads to a larger enrichment in glutamine than in glutamate, suggesting a preferential astrocyte metabolism of C8 [28, 30]. Here we extend this finding to acute brain slices, where we show that metabolism not only of C8, but also of C10, is promoting glutamine synthesis in astrocytes. The preferential astrocyte metabolism of MCFAs has further been confirmed in cell cultures, where only astrocytes were able to metabolize [1-14C]C8, whereas neurons and oligodendrocytes were not [29]. Here we also report that the extent of C8 and C10 metabolism in brain slices, based on 13C accumulation in TCA cycle intermediates and amino acids, was generally comparable. A recent study assessed CO2 generation from metabolism of [1-14C]C8/C10 in the neuronal-like SH-SY5Y cell line. Based on the CO2 generation, the authors reported that the oxidation of C8 was around 6 times higher than that of C10 [41], which is in contrast to our findings in the acute brain slices where the extent of C8 and C10 metabolism was comparable (Fig. 1). This discrepancy is likely explained by the different preparations, as the SH-SY5Y is a neuroblastoma cell line with neuronal-like properties [46], whereas brain slices are a complex preparation containing all types of cerebral cells, including the primary cells of MCFA metabolism in the brain, the astrocytes. When the brain slices were provided both C8 and C10, we found that metabolism of C10 was predominant over that of C8 (Fig. 3), which may indicate competition in mitochondrial transport or metabolism of C8 and C10. It has also recently been reported that CPT-1 inhibition reduced the oxidative metabolism of both C8 and C10 in the SH-SY5Y cells [41]. This is surprising as MCFAs metabolism should be carnitine independent [2, 47], which we also found to be the case in brain slices (Fig. 4). Our observation that...
C10 was preferred over C8 as a metabolic substrate in the brain slices may instead be explained by differential substrate affinities for C8 and C10 of the enzymes catalyzing MCFA metabolism. Indeed, the enzyme initiating mitochondrial MCFA β-oxidation, the medium-chain acyl-CoA dehydrogenase, has been shown to have a higher substrate affinity towards C10 than C8 [48]. Furthermore, C10 also has a larger membrane permeability than C8, due to the longer carbon chain, which increases diffusion across the cell and mitochondrial membranes [40], which may also contribute to the observed preferential metabolism of C10 over C8 [48]. Furthermore, C10 also has a larger membrane permeability than C8, due to the longer carbon chain, which increases diffusion across the cell and mitochondrial membranes [40], which may also contribute to the observed preferential metabolism of C10 over C8 [48]. Although astrocytes are the main cellular compartment of MCFA metabolism, it was recently demonstrated that a subset of neurons in the hypothalamus have a large capacity for C8 oxidation [49]. In these hypothalamic neurons, C8 metabolism regulate neuronal excitability and food intake, which underlines the complexity and importance of regional brain energy metabolism. Further studies are needed to explore other potential functions of MCFA metabolism in the brain, both on a regional and cell-specific level.

**Mitochondrial effects of C8 and C10 in astrocytes**

Both C8 and C10 can be utilized as mitochondrial fuels in several different tissues including the brain [2, 4]. Here, we found that the addition of C8, C10 and the combination was able to stimulate both basal and uncoupled mitochondrial respiration in cultured astrocytes (Fig. 2). Our findings are in contrast to a report by Thevenet et al. showing that acute exposure to C8 and C10 was unable to stimulate the OCR of cultured induced pluripotent stem cell-derived human neurons and astrocytes [50]. Although not significant, the study reported that C8 had a tendency to increase the overall OCR, whereas C10 had a tendency towards reduced ATP-dependent OCR, in the cultured astrocytes [50]. These tendencies are in line with our findings that C8 increased the respiration linked to ATP production, whereas C10 increased the proton leak in the cultured astrocytes. Our observations further confirm a recent study in cultured astrocytes, showing that both C8 and C10 were able to increase basal respiration, whereas C10 selectively increased the proton leak relative to pyruvate oxidation [32]. The proton leak is defined as...
the flow of protons across the inner mitochondrial membrane unrelated to ATP synthesis and is intimately coupled to the generation of harmful reactive oxygen species (ROS) [38]. Intriguingly, a mild increase in the proton leak is protective against ROS generation [38, 51] and the elevated proton leak induced by C10 may therefore have antioxidant properties. Furthermore, C10 has been shown to exert multiple other antioxidant effects, including regulation of antioxidant gene expression [32], catalase activity [52] and glutathione content [53]. Treatment with C10, but not C8, in SH-SY5Y cells has also been shown to increase mitochondrial biogenesis [52], potentially via PPAR signaling [54, 55]. Collectively these findings show that C10 is not just a mitochondrial fuel, but can exert several beneficial effects on mitochondrial bioenergetics via different mechanisms.

**Effects of C8 and C10 metabolism on neuron-astrocyte metabolic coupling and neurotransmitter recycling**

Energy and neurotransmitter metabolism in neurons and astrocytes is tightly coupled [18]. Fatty acid transfer between neurons and astrocytes is gaining attention [56, 57] and MCFAs have also been suggested to take part in the transcellular metabolic coupling [3]. Several studies have shown that C10 is able to induce astrocyte lactate production, whereas C8 stimulates astrocyte ketone body production [50, 53, 58, 59], both of which may be transferred to neurons to support oxidative metabolism. Another crucial metabolite transferred from astrocytes to neurons is glutamine, which serves an essential role as the primary precursor of neuronal glutamate and GABA synthesis [20–22, 44]. When we inhibited glutamine synthesis from C8 and C10 metabolism in brain slices using MSO, the 13C accumulation in glutamine and GABA was decreased, while it was elevated for the rest of the measured metabolites (Fig. 5). We have previously described similar effects of MSO on metabolism of the well-known astrocytic substrate [1,2-13C]acetate [43], further supporting that astrocytes are the primary cellular compartment for C8 and C10 metabolism. Furthermore, we have previously demonstrated that transfer of astrocyte-derived glutamine to neurons is maintained in our slice incubation set-up [43, 60], implying that the decreased neuronal GABA synthesis in the presence of MSO is indeed caused by the absent astrocyte glutamine supply. Insufficient astrocyte glutamine

---

**Fig. 6** Overview of C8 and C10 metabolism in brain slices. (1) Both C8 and C10 metabolism was unaffected by the carnitine palmitoyltransferase I (CPT-1) inhibitor etomoxir. (2) When provided alone, the extent of C8 and C10 metabolism was comparable, but when provided together C10 was preferred over C8 as a metabolic substrate. (3) In cultured astrocytes, C8 selectively increased the respiration linked to ATP production, whereas the presence of C10 elevated the mitochondrial proton leak. (4) Both C8 and C10 is utilized for glutamine synthesis. Since glutamine is selectively synthesized in astrocytes, this signifies that astrocytes are the primary cellular compartment for C8 and C10 metabolism. (5) When glutamine synthesis from C8 and C10 metabolism was inhibited, a selective reduction was observed in neuronal GABA synthesis. This demonstrates that the glutamine generated by astrocyte metabolism of C8 and C10 is used for neuronal GABA synthesis. (6) The ketone body β-hydroxybutyrate (βHB) did not compete, to any significant extent, with C8 and C10 metabolism supporting the notion that ketone bodies are primarily utilized by neurons.
and C10 are primarily metabolized in astrocytes, S2). These observations are in line with the notion that C8 and C10 could support neuronal signaling in hippocampal brain slices during low-glucose conditions [63]. However, the same study reported that C8 increased the neuronal recovery rate [63], which in the light of the present study, could be mediated via increased astrocyte glutamine supply. In addition to direct metabolic effects, C10 may serve several signaling purposes in the brain [59, 64], and is at low levels to inhibit AMPA receptors [65], suggesting multiple mechanisms underlying the anti-epileptic effects of C10. Finally, astrocyte dysfunction is gaining attention in several neurodegenerative diseases [66] and we have demonstrated inadequate astrocyte glutamine supply in mouse models of both Alzheimer’s and Huntington’s disease [25, 60]. Interestingly, C8 and C10 supplementation has been shown to improve cognitive function in patients with mild cognitive impairment and Alzheimer’s disease [6–8] and are gaining attention in several other diseases [5]. C8 and C10 could exert these beneficial effects, in part, by enhancing astrocyte glutamine synthesis and hereby improve neuronal neurotransmitter homeostasis. These notions encourage further studies into the molecular and cellular mechanisms of MCFA supplementation in neurodegeneration and other diseases.

**Abbreviations**

- [U-13C]βHB: [U-13C]β-hydroxybutyrate
- C8: Octanoic acid
- C10: Decanoic acid
- CPT-1: Carnitine palmitoyltransferase I
- GS: Glutamine synthetase
- MCT: Medium-chain triglyceride
- MSO: Methionine sulfoximine
- OCR: Oxygen consumption rate
- PAG: Phosphate-activated glutaminase
- TCA: Tricarboxylic acid

**Supplementary Information**

The online version contains supplementary material available at [https://doi.org/10.1186/s13041-021-00842-2](https://doi.org/10.1186/s13041-021-00842-2).

**Acknowledgements**

John Velde Andersen is acknowledged for excellent technical support. The Scholarship of Peter & Emma Thomsen is gratefully acknowledged for personal financial support to JVA & EWW.

**Authors’ contributions**

JVA performed all slice incubations. JVA and EJ performed Seahorse experiments. EW and NU assisted with sample analysis. All authors interpreted the data and provided critical input to the final manuscript. JVA, KB & BIA conceived the overall project and JVA wrote the original manuscript. All authors read and approved the final manuscript.

**Funding**

This study was financially supported by the Lundbeck Foundation (JVA, R333-2019-1244), the Hørslev Foundation (BIAG) and the Australian National Health and Medical Research Council (KB, APP1186025).

**Availability of data and materials**

All data of this study is available from the corresponding authors upon request.

**Declarations**

**Ethics approval and consent to participate**

Experiments were approved by the Danish National Ethics Committee and performed in accordance with the European Convention (ETS 123 of 1986).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen S, Denmark.

2. Department of Pharmacology, School of Biomedical Sciences, The University of Queensland, St. Lucia, Australia.

**Received:** 28 May 2021  **Accepted:** 22 August 2021  **Published online:** 03 September 2021

**References**

1. Dienel GA. Brain glucose metabolism: integration of energetics with function. Physiol Rev. 2019;99:949–1045.
2. Schönfeld P, Wojcicki L. Short- and medium-chain fatty acids in energy metabolism: the cellular perspective. J Lipid Res. 2016;57:943–54.

3. Romano A, Koczwar JA, Galilei CA, Vergara D, Miccioni D, Bonaventura MV, Gaetani S, Giudetti AM. Fats for thoughts: an update on brain fatty acid metabolism. Int J Biochem Cell Biol. 2017;84:40–5.

4. Panov A, Orynbayeva Z, Vavilov V, Lyakhovich V. Fatty acids in energy metabolism of the central nervous system. Biochem Res Int. 2014;2014:472459.

5. Cunanne SC, Trushina E, Morland C, Pignone A, Casadesus G, Andrews ZB, Beal MF, Berghersen LH, Brinton RD, de la Monte S, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;19:609–33.

6. Henderson ST, Vogel JL, Barrett LJ, Garvin FC, Jones JH, Costamini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicontroller trial. Nutr Metab. (Lond). 2009;6:31.

7. Fortier M, Castellano CA, Coteau E, Langlois F, Bocci C, St-Pierre V, Vandenbergh B, Bernier M, Roy M, Descoteaux M, et al. A ketogenic diet improves brain energy and some measures of cognition in mild cognitive impairment. Alzheimers Dement. 2019;15:625–34.

8. Coteau E, Castellano CA, Richard MA, Fortier M, Nugent S, Lepage M, Duchesne S, Whittingstall K, Turcotte EE, Bocci C, et al. Ketogenic medium chain triglycerides increase brain metabolism in Alzheimer’s disease. J Alzheimer’s Dis. 2018;64:651–61.

9. Augustin K, Khabbush A, Williams S, Eaton S, Orford M, Cross JH, Heales SJR, Walker MC, Williams RB. MsB: Action of mechanism for the medium chain triglyceride ketogenic diet in neurological and metabolic disorders. Lancet Neurol. 2018;17:84–93.

10. Borges K, Kaul N, Germaine J, Kwan P, O’Brien TJ. Randomized trial of addition of medium chain triglycerides in adults with refractory epilepsy. Epilepsia Open. 2019;4:153–63.

11. Han FY, Conboy-Schmidt L, Rybachuk Y, Volk HA, Zanghi B, Pan Y, Borges K. Dietary medium chain triglycerides for management of epilepsy: new data from human, dog, and rodent studies. Epilepsia. 2021;62:1790–1806.

12. Thavendiranathan P, Mendonca A, Dell C, Likhodi SS, Musa K, Irazoqui C, Cunanne SC, Burnham WM. The MCT ketogenic diet effects on animal seizure models. Exp Neurol. 2003;161:696–703.

13. Likhodi SS, Musa K, Mendonca A, Dell C, Burnham WM, Cunanne SC. Dietary fat, ketosis, and seizure resistance in rats on the ketogenic diet. Epilepsia. 2000;41:1400–10.

14. Oldendorf WH. Carrier-mediated blood-brain barrier transport of short-chain monacryloxylic organic acids. Am J Physiol. 1973;224:1450–3.

15. Spector R. Fatty acid transport through the blood-brain barrier. J Neurochem. 1988;50:639–43.

16. Waż P, Socala K, Nieoczym D, Luszczki JJ, Zarnowska I, Zarnowski T, Czuczwar SJ, Gasior M. Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice. Neuropharmacology. 2012;62:1882–92.

17. Waż P, Socala K, Nieoczym D, Zarnowska I, Zarnowski T, Czuczwar SJ, Gasior M. Acute anticonvulsant effects of capric acid in seizure tests in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2015;57:110–21.

18. Barros LF, Brown A, Swanson RA. Glia in brain energy metabolism: a perspective. Glia. 2018;66:1134–7.

19. Schousboe A, Bak LK, Waagepetersen HS. Astrocytic control of biosynthesis and turnover of the neurotransmitters glutamate and GABA. Front Endocrinol (Lausanne). 2013;4:102.

20. Andersen JV, Markussen KH, Jakobsen E, Schousboe A, Waagepetersen HS, Rosenberg PA, Aldana BL. Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration. Neuropharmacology. 2021;15:108719.

21. Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABA-glutamate cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem. 2006;98:641–53.

22. Hertz L. The glutamate-glutamine (GABA) cycle: importance of late postnatal development and potential reciprocal interactions between biosynthesis and degradation. Front Endocrinol (Lausanne). 2013;4:59.

23. Eid T, Thomas MJ, Spencer DD, Runden-Pran E, Lai JC, Malthankar GV, Kim JH, Danbolt NC, Ottersen OP, de Lanerolle NC. Loss of glutamine synthetase in the human epileptic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy. Lancet. 2004;363:28–37.

24. Eid T, Ghosh A, Wang Y, Beckstrom H, Zaveri HP, Lee TS, Lai JC, Malthankar-Phatak GH, de Lanerolle NC. Recurrent seizures and brain pathology after inhibition of glutamine synthetase in the hippocampus in rats. Brain. 2008;131:2061–70.

25. Skotte NH, Andersen JV, Santos A, Aldana BL, Willert CW, Norremolle A, Waagepetersen HS, Nielsen ML. Integrative characterization of the R6/2 mouse model of Huntington’s disease reveals dysfunctional astrocyte metabolism. Cell Rep. 2018;23:2211–24.

26. Norenborg MD, Martinez-Hernandez A. Fine structural localization of glutamine synthetase in astrocytes of rat brain. Brain Res. 1979;161:303–10.

27. McKenna MC. Glutamine pays its own way in astrocytes. Front Endocrinol (Lausanne). 2014;3:191.

28. Cremer JE, Teal HM, Heath DF, Cavanagh JB. The influence of portocaval anastomosis on the metabolism of labelled octanoate, butyrate and leucine in rat brain. J Neurochem. 1977;28:215–22.

29. Edmond J, Robbins RA, Bergstrom JD, Cole RA, de Vellis J. Capacity for substrate utilization in oxidative metabolism by neurons, astrocytes, and oligodendrocytes from developing brain in primary culture. J Neurosci. 1987;18:551–61.

30. Ebert D, Haller RG, Walton ME. Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. J Neurosci. 2003;23:9928–35.

31. McNair LF, Konolfit R, Walls AB, Andersen JV, Aldana BL, Nissen JD, Schousboe A, Waagepetersen HS. Metabolic characterization of acutely isolated hippocampal and cerebral cortical slices using [U-13C]glucose and [1–13C]acetate as substrates. Neurochem Res. 2017;42:810–26.

32. Tan KN, Carrasco-Pozo C, McDonald TS, Puchowicz M, Borges K. Tridecanoic acid is anticonvulsant, antioxidant, and improves mitochondrial function. J Cereb Blood Flow Metab. 2017;37:2035–48.

33. Naresh SS, Rankow RA, Gao B, Wall GE, Rae C. Modulation of brain metabolism by very low concentrations of the commonly used drug delivery vehicle dimethyl sulfoxide (DMSO). J Neurosci Res. 2008;86:208–14.

34. Walls AB, Bak LK, Sonnevald U, Schousboe A, Waagepetersen HS. Metabolic mapping of astrocytes and neurons in culture using stable isotopes and gas chromatography-mass spectrometry (gc-ms). In brain energy metabolism neuromethods, vol 90. In: Hrnčíř J, Waagepetersen HS, eds. New York: Humana Press, 2014.

35. Andersen JV, Christensen SK, Nissen JD, Waagepetersen HS. Improved cerebral energetics and ketone body metabolism in db/db mice. J Cereb Blood Flow Metab. 2017;37:1137–47.

36. Andersen JV, Christensen SK, Aldana BL, Nissen JD, Tanila H, Waagepetersen HS. Alternations in cerebral cortical glucose and glutamine metabolism precedes amyloid plaques in the APPsw/PSEN1de9 mouse model of Alzheimer’s disease. Neurochem Res. 2017;42:1589–98.

37. Andersen JV, Jakobsen E, Westi EW, Lie MEK, Voss CM, Aldana BL, Schousboe A, Wellendorph P, Bak LK, Pinborg LH, Waagepetersen HS. Extensive astrocyte metabolism of γ-aminobutyric acid (GABA) sustains glutamine synthesis in the mammalian cerebral cortex. Glia. 2020;68:2601–12.

38. DiVakaruni AS, Brand MD. The regulation and physiology of mitochondrial proton leak. Physiology (Bethesda). 2011;2:192–205.

39. Pan JW, de Graaf RA, Petersen KE, Shulman GI, Hetherington HP, Rothman DL, [2,4–13 C2]-beta-hydroxybutyrate metabolism in human brain. J Cereb Blood Flow Metab. 2002;22:890–8.

40. Kamp F, Hamilton JA. How fatty acids of different chain length enter and leave cells by free diffusion. Prostaglandins Leukot Essent Fatty Acids. 2006;75:149–59.

41. Khabbush A, Orford M, Tsai YC, Rutherford T, Walls AB, Andersen JV, Aldana BL, Nissen JD, Schousboe A, Waagepetersen HS. Metabolic characterization of acutely isolated hippocampal and cerebral cortical slices using [U-13C]glucose and [1–13C]acetate as substrates. Neurochem Res. 2017;42:810–26.
45. Geyer RP, Matthews LW, Stare FJ. Metabolism of emulsified trilaurin (C14:0) and octanoic acid (C14:0) by rat tissue slices. J Biol Chem. 1949;180:1037–45.

46. Xiccò H, Wierenga B, Martens GJ. The S9-SYSY cell line in Parkinson’s disease research: a systematic review. Mol Neurodegener. 2017;12:10.

47. Longo N, Frigeni M, Pasqualli M. Carminative transport and fatty acid oxidation. Biochim Biophys Acta. 2016;1863:2422–35.

48. Nandy A, Kieweg V, Krautle FG, Voek P, Küchler B, Bros P, Kim JJ, Rasched I, Ghisla S. Medium-long-chain chimeric human Acyl-CoA dehydrogenase: medium-chain enzyme with the active center base arrangement of long-chain Acyl-CoA dehydrogenase. Biochemistry. 1996;35:12402–11.

49. Haynes VR, Michal NJ, van den Top M, Zhao FY, Brown RD, De Souza D, Dodd GT, Spanswick D, Watt MJ. A Neural basis for Octanoinic acid regulation of energy balance. Mol Metab. 2020;34:54–71.

50. Thevenet J, De Marchi U, Domingo JS, Christinat N, Bultot L, Lefebvre G, Thevenet J, Descombes P, Masoodi M, Wiederkehr A. Medium-chain fatty acids inhibit mitochondrial metabolism in astrocytes promoting astrocyte-neuron lactate and ketone body shuttle systems. Fasebj J. 2016;30:1913–26.

51. Brooks PS. Mitochondrial H(+) leak and ROS generation: an odd couple. Free Radic Biol Med. 2005;38:12–23.

52. Hughes SD, Kanabus M, Anderson G, Hargreaves IP, Rutherford T, O’Dernell M, Cross JH, Rahman S, Eaton S, Heales SJ. Differential metabolism of medium-chain fatty acids in differentiated human-induced pluripotent stem cell-derived astrocytes. Front Physiol. 2019;10:657.

53. Sonnay S, Chakrabarti A, Thevenet J, Wiederkehr A, Christinat N, Masoodi M. Differential metabolism of medium-chain fatty acids in differentiated human-induced pluripotent stem cell-derived astrocytes. Front Physiol. 2019;10:657.

54. Malapaka RR, Khoo S, Zhang J, Choi JH, Zhou XE, Xu Y, Gong Y, Li J, Yong EL, Chalmers MJ, et al. Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J Biol Chem. 2012;287:183–95.

55. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R. PPAR-gamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int. 2009;55:496–504.

56. Ioannou MS, Jackson J, Sheu SH, Chang CL, Wiegell AV, Liu H, Pasolli HA, Xu CS, Pang S, Matthies D, et al. Neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity. Cell. 2019;171:1522–1535.e1514.

57. Qi G, Mi Y, Shi X, Gu H, Brinton RD, Yin F. ApoE4 impairs neuron-astrocyte coupling of fatty acid metabolism. Cell Rep. 2021;34:10857–2.

58. Damiano F, De Benedetto GE, Longo S, Giannotti L, Fico D, Siculella L, Giudetti AM. Decanoinic acid and not octanoic acid stimulates fatty acid synthesis in U87MG glioblastoma cells: a metabolomics study. Front Neurosci. 2020;14:783.

59. Lee N, Sa M, Hong YR, Lee CJ, Koo J. Fatty acid increases CAMP-dependent lactate and MAO-B-dependent GABA production in mouse astrocytes by activating a (G)αi protein-coupled receptor. Exp Neurol. 2018;27:365–76.

60. Andersen JV, Christensen SK, Westi EW, Diaz-delCastillo M, Tanila H, Schousboe A, Aldana BI, Waagepetersen HS. Deficient astrocyte metabolism impairs glutamine synthesis and neurotransmitter homeostasis in a mouse model of Alzheimer’s disease. Neuropadiol. Dis. 2021;148:105198.

61. Yoon BE, Woo J, Chun YE, Chun H, Jo S, Bae JY, An H, Min JO, Oh SJ, Han KS, et al. Gial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition. J Physiol. 2014;592:4951–68.

62. Kwak H, Koh W, Kim S, Song K, Shin JI, Lee JI, Lee EH, Bae JY, Ha GE, Oh JE, et al. Astrocytes control sensory acuity via tonic inhibition in the thalamus. Neuron. 2020;108:691–706.e610.

63. Page KA, Williamson A, Yu N, McNay EC, Dzuira J, McCrimmon RJ, Sherwin RS. Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia. Diabetes. 2009;58:1237–44.

64. Warren EC, Dooves S, Lugarà E, Damstra-Oddy J, Schaf J, Heine VM, Walker MC, Williams RSB. Decanoinic acid inhibits mTORC1 activity independent of glucose and insulin signaling. Proc Natl Acad Sci U S A. 2020;117:23617–25.

65. Chang P, Augustin K, Boddum K, Williams S, Sun M, Tschak JA, Hardege JD, Chen PE, Walker MC, Williams RS. Seizure control by decanoic acid through direct AMPA receptor inhibition. Brain. 2016;139:431–43.

66. Bennett ML, Viane AN. What are activated and reactive glia and what is their role in neurodegeneration? Neurobiol Dis. 2021;148:105172.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.